The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer

The use of programmed cell-death protein 1 (PD-1)/programmed cell-death ligand 1 (PD-L1) inhibitors is the standard therapy for the first-line or second-line treatment of patients with non-small-cell lung cancer (NSCLC). In contrast to current traditional treatments such as chemotherapy or radiother...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Ther Adv Med Oncol
Egile Nagusiak: Qu, Jingjing, Mei, Quanhui, Liu, Li, Cheng, Tianli, Wang, Peng, Chen, Lijun, Zhou, Jianying
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: SAGE Publications 2021
Gaiak:
Immunotherapy for Lung Cancer: Special Collection Progress, Opportunities and Challenges
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7890731/
https://ncbi.nlm.nih.gov/pubmed/33643442
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835921992968
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak